News

AMPAC plans $25 million expansion at is Petersburg plant, adding 150 new jobs

AMPAC Fine Chemicals announced a $25 million expansion of its operations that is expected to add more than 150 new jobs.

The California-based company is a top U.S. manufacturer of active pharmaceutical ingredients. The plant in Petersburg previously was owned by Boehringer Ingelheim Chemicals Inc., which closed it in 2014, but AMPAC reopened the site in 2019.

AMPAC employs about 100 people at the site now, having hired about 50 employees this year to ramp up production of pharmaceutical ingredients. The company expects to add the additional 150 jobs over the next two to three years.

The AMPAC plant is part of a larger, planned node of pharmaceutical manufacturing. The Richmond-based pharmaceutical development company Phlow Corp., which has a partnership with AMPAC, also is planning a production facility adjacent to the AMPAC plant.

Founded last year, Phlow has developed manufacturing processes that reduce the cost of production for active pharmaceutical ingredients. In May 2020, Phlow announced it had received a $354 million federal contract to help build a national, strategic reserve of essential medicines and to make active ingredients for more than a dozen medicines used to treat patients with COVID-19.

Another participant in the pharmaceutical manufacturing partnership is Civica Inc., a nonprofit organization formed by various U.S. health care providers to address chronic, generic drug shortages.

Civica announced in January that it plans to invest $124.5 million to establish its first in-house pharmaceutical manufacturing operation also on Normandy Drive in Petersburg.

Recent News

05/14/2025

Civica to start Chesterfield lab construction this summer, eyes Petersburg plant expansion

Nearly three years after announcing plans to build a laboratory in Chesterfield to support its manufacturing operations in Petersburg, Civica Rx is readying plans to kick off the project’s construction. The Utah-based nonprofit drugmaker said it will break ground this summer on a 50,000-square-foot facility at 11731 Meadowville Lane, in the Meadowville Technology Park near Chester.

05/07/2025

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor. The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes. The name of the investor was not disclosed, but Adial said a “health

05/07/2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office. This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules